NATCO Pharma Ltd completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Ltd

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) ("NATCO") announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited ("Adcock Ingram"), a leading South African pharmaceutical and healthcare company.

With the completion of this transaction, NATCO's shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through NATCO Pharma South Africa Proprietary Limited, NATCO's wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around ₹ 1,060 crores at the transaction exchange rate.

Strategic milestone in NATCO's African growth journey

The completion of the additional stake acquisition marks another significant milestone in NATCO's long-term Africa strategy.

NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram's delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025.

Pursuant to that, NATCO's Board further approved the acquisition of an additional 13.25% stake in July 2026, and the transaction has now been completed following the satisfaction of customary closing conditions and regulatory requirements.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 971.85 as compared to the previous close of Rs. 979.70. The total number of shares traded during the day was 13553 in over 730 trades.

The stock hit an intraday high of Rs. 983.65 and intraday low of 966.05. The net turnover during the day was Rs. 13193049.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals Acquisition AdcockIngramHoldingsProprietary